Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96

HOS-116606 · Präparat HOS-094447

95  Saquinavir # It is not recommended to combine darunavir AUC ↓ 26% 1,000 mg twice daily # darunavir Cmin ↓ 42% PREZISTA co-administered with # darunavir Cmax ↓ 17% low dose ritonavir with saquinavir. saquinavir AUC ↓ 6% saquinavir Cmin ↓ 18% PREZISTA co-administered with cobicistat should not be used in saquinavir Cmax ↓ 6% combination with another antiretroviral agent that requires Saquinavir: comparison of pharmacoenhancement by means saquinavir/ritonavir 1,000/100 mg twice of co-administration with an daily vs. saquinavir/darunavir/ritonavir inhibitor of CYP3A4 (see section 1,000/400/100 mg twice daily 4.5). Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily. HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir† Lopinavir/ritonavir lopinavir AUC ↑ 9% Due to a decrease in the exposure 400/100 mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%, lopinavir Cmax ↓ 2% appropriate doses of the darunavir AUC ↓ 38%‡ combination have not been darunavir Cmin ↓ 51% ‡ established. Hence, concomitant ‡ use of boosted PREZISTA and the darunavir Cmax ↓ 21% Lopinavir/ritonavir combination product lopinavir AUC ↔ 533/133.3 mg twice daily lopinavir/ritonavir is lopinavir Cmin ↑ 13% contraindicated (see section 4.3). lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% ‡ based upon non dose normalised values CCR5 ANTAGONIST Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be 150 mg twice dailymaraviroc Cmin ND 150 mg twice daily when maraviroc Cmax ↑ 129% co-administered with boosted darunavir, ritonavir concentrations were PREZISTA. consistent with historical data α1-ADRENORECEPTOR ANTAGONIST Alfuzosin Based on theoretical considerations Co-administration of boosted PREZISTA is expected to increase PREZISTA and alfuzosin is alfuzosin plasma concentrations. contraindicated (see section 4.3). (CYP3A inhibition) ANAESTHETIC Alfentanil Not studied. The metabolism of alfentanil The concomitant use with boosted is mediated via CYP3A, and may as such PREZISTA may require to lower be inhibited by boosted PREZISTA. the dose of alfentanil and requires monitoring for risks of prolonged or delayed respiratory depression.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) protease (HOS-085623) cobicistat (HOS-088111) saquinavir (HOS-084522) maraviroc (HOS-086186) ritonavir (HOS-084521)